$CERS,,,New contract announced today (See Below),,,Earnings report should be out on 8/03 after-hours,, chart looks good,,price per share closed today at $2.22, down $.04. Support is sitting at $2.20, Money Flow Index has just begun north, stochastic and macD are both positive. Bollinger bands have tightened and am looking for a breakout above the upper band. If your not ready to jump in, I would suggest you keep your eyes on this as it gets closer to the 8/03 Earnings announcement. Maybe we can get an indication of how things look by watching the pps. All this in my opinion and Good luck trading.
CERUS ANNOUNCES EXPANDED SUPPLY AGREEMENT WITH FRENCH NATIONAL BLOOD SERVICE
08/01/2017
New contracts enable broad adoption of the INTERCEPT Blood System for platelets in France
CONCORD, California--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) announced today the signing of two, new, expanded contracts with Établissement Français du Sang (EFS), the French National Blood Service, for the INTERCEPT Blood System. One contract covers the supply of INTERCEPT Platelet kits while the other is for the purchase of additional Illuminators to help support the roll-out to new regions. The initial term of this platelet kit supply agreement is two years with two one-year extension options, supporting INTERCEPT platelet production in all EFS regional centers.
In January, the EFS was informed of the Ministry of Health’s decision that the INTERCEPT Platelet system should be deployed for the control of bacterial infections transmitted by transfusion, in accordance with a prior December 2016 recommendation by France’s regulatory authority, ANSM, the French National Agency for Medicines and Health Products Safety.
“We are proud that our decade long relationship with the EFS has led to an expanded supply agreement that supports a new standard of care,” said William ‘Obi” Greenman, Cerus’ president and chief executive officer. “Currently, approximately 10% of the annual platelet production in France is treated with the INTERCEPT system. We look forward to working with EFS to implement pathogen reduction throughout their system. In support of this broad roll-out to new regions, we plan to ramp up production of INTERCEPT Platelet kits to ensure ample supply,” continued Greenman.
The EFS produces approximately 330,000 units of platelets annually across 12 regional centers in continental France and 3 overseas territories. The INTERCEPT Blood System for platelets has been used in France since 2006, and is currently used in the Alsace region, as well as throughout overseas French territories including the islands of La Reunion, Guadeloupe, and Martinique. Implementation in the island territories was driven by the need to maintain a safe platelet supply during outbreaks of chikungunya, dengue and Zika in these tropical regions. In addition, INTERCEPT is utilized by the French Army.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See www.cerus.com for information about Cerus.
CERUS ANNOUNCES EXPANDED SUPPLY AGREEMENT WITH FRENCH NATIONAL BLOOD SERVICE
08/01/2017
New contracts enable broad adoption of the INTERCEPT Blood System for platelets in France
CONCORD, California--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) announced today the signing of two, new, expanded contracts with Établissement Français du Sang (EFS), the French National Blood Service, for the INTERCEPT Blood System. One contract covers the supply of INTERCEPT Platelet kits while the other is for the purchase of additional Illuminators to help support the roll-out to new regions. The initial term of this platelet kit supply agreement is two years with two one-year extension options, supporting INTERCEPT platelet production in all EFS regional centers.
In January, the EFS was informed of the Ministry of Health’s decision that the INTERCEPT Platelet system should be deployed for the control of bacterial infections transmitted by transfusion, in accordance with a prior December 2016 recommendation by France’s regulatory authority, ANSM, the French National Agency for Medicines and Health Products Safety.
“We are proud that our decade long relationship with the EFS has led to an expanded supply agreement that supports a new standard of care,” said William ‘Obi” Greenman, Cerus’ president and chief executive officer. “Currently, approximately 10% of the annual platelet production in France is treated with the INTERCEPT system. We look forward to working with EFS to implement pathogen reduction throughout their system. In support of this broad roll-out to new regions, we plan to ramp up production of INTERCEPT Platelet kits to ensure ample supply,” continued Greenman.
The EFS produces approximately 330,000 units of platelets annually across 12 regional centers in continental France and 3 overseas territories. The INTERCEPT Blood System for platelets has been used in France since 2006, and is currently used in the Alsace region, as well as throughout overseas French territories including the islands of La Reunion, Guadeloupe, and Martinique. Implementation in the island territories was driven by the need to maintain a safe platelet supply during outbreaks of chikungunya, dengue and Zika in these tropical regions. In addition, INTERCEPT is utilized by the French Army.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See www.cerus.com for information about Cerus.
1
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
